February 6, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Dimension Therapeutics Inc (NASDAQ:DMTX) shares over potential securities laws violations by Dimension Therapeutics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Dimension Therapeutics Inc (NASDAQ:DMTX) concerning whether a series of statements by Dimension Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Dimension Therapeutics, Inc. is a gene therapy company that is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations.

Dimension Therapeutics Inc reported that its annual Total Revenue rose from $2.75 million in 2014 to $7.75 million in 2015 and that its Net Loss increased from $12.97 million in 2014 to $35.06 million in 2015.

On January 31, 2017, Dimension Therapeutics Inc (NASDAQ:DMTX) announced preliminary topline safety and early efficacy results of Dimensions multi-center phase 1/2 study of DTX101 for the treatment of adult patients with moderate/severe to severe hemophilia B. DTX101, Dimensions lead AAV candidate, is designed to deliver stable expression of blood clotting Factor IX (FIX) in patients with hemophilia B, a rare genetic bleeding disorder resulting from a deficiency in FIX.

Shares of Dimension Therapeutics Inc (NASDAQ:DMTX) declined from $4.50 per share in January 30, 2017, to $1.90 per share on January 31, 2017.